Hereditary Angioedema Therapeutics
1. Ekterly patent expiration
Treatment: Treatment of acute attacks of hereditary angioedema (hae) in adults and pediatric patients 12 years of age and older
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11084809 | KALVISTA | NA |
Nov, 2035
(9 years from now) | |
| US10364238 | KALVISTA | NA |
Nov, 2035
(9 years from now) | |
| US11001578 | KALVISTA | NA |
Nov, 2035
(9 years from now) | |
| US11230537 | KALVISTA | NA |
Dec, 2037
(11 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11198691 | KALVISTA | NA |
Nov, 2035
(9 years from now) | |
| US10611758 | KALVISTA | NA |
Nov, 2035
(9 years from now) | |
| US11739068 | KALVISTA | NA |
Jun, 2037
(11 years from now) | |
| US11234939 | KALVISTA | NA |
Jan, 2039
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 03, 2030 |
Drugs and Companies using SEBETRALSTAT ingredient
NCE-1 date: 03 July, 2029
Market Authorisation Date: 03 July, 2025
Dosage: TABLET
More Information on Dosage
EKTERLY family patents
2. Firazyr patent expiration
Treatment: Treatment of pathological state by antagonizing bradykinin receptor including treatment of acute attacks of hereditary angioedema (hae)
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5648333 | TAKEDA PHARMS USA | Peptides having bradykinin antagonist action |
Jul, 2014
(11 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 25, 2016 |
| Orphan Drug Exclusivity(ODE) | Aug 25, 2018 |
| Orphan Drug Exclusivity(ODE-14) | Aug 25, 2018 |
Drugs and Companies using ICATIBANT ACETATE ingredient
NCE-1 date: 26 August, 2015
Market Authorisation Date: 25 August, 2011
Dosage: INJECTABLE
How can I launch a generic of FIRAZYR before it's drug patent expiration?
More Information on Dosage
FIRAZYR family patents
3. Orladeyo patent
expiration
Treatment: Prophylaxis to prevent attacks of hereditary angioedema (hae) in adult and pediatric patients 12 years of age and older; Prophylaxis to prev...
Can you believe ORLADEYO received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10125102 | BIOCRYST | Human plasma kallikrein inhibitors |
Apr, 2035
(9 years from now) | |
| US10662160 | BIOCRYST | Crystalline salts of a plasma kallikrein inhibitor |
Nov, 2039
(13 years from now) | |
| US12116346 | BIOCRYST | Human plasma kallikrein inhibitors |
Mar, 2035
(9 years from now) | |
| US10329260 | BIOCRYST | Human plasma kallikrein inhibitors |
Mar, 2035
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11117867 | BIOCRYST | Crystalline salts of a plasma kallikrein inhibitor |
Nov, 2039
(13 years from now) | |
| US11230530 | BIOCRYST | Human plasma kallikrein inhibitors |
Mar, 2035
(9 years from now) | |
| US11708333 | BIOCRYST | Human plasma kallikrein inhibitors |
Mar, 2035
(9 years from now) | |
| US12344585 | BIOCRYST | NA |
Nov, 2039
(13 years from now) | |
| US10689346 | BIOCRYST | Human plasma kallikrein inhibitors |
Mar, 2035
(9 years from now) | |
| US11618733 | BIOCRYST | Crystalline salts of a plasma kallikrein inhibitor |
Nov, 2039
(13 years from now) | |
|
US12344585 (Pediatric) | BIOCRYST | NA |
May, 2040
(14 years from now) | |
|
US11618733 (Pediatric) | BIOCRYST | NA |
May, 2040
(14 years from now) | |
|
US12116346 (Pediatric) | BIOCRYST | NA |
Sep, 2035
(9 years from now) | |
|
US11117867 (Pediatric) | BIOCRYST | NA |
May, 2040
(14 years from now) | |
|
US11708333 (Pediatric) | BIOCRYST | NA |
Sep, 2035
(9 years from now) | |
|
US11230530 (Pediatric) | BIOCRYST | NA |
Sep, 2035
(9 years from now) | |
|
US10125102 (Pediatric) | BIOCRYST | NA |
Oct, 2035
(9 years from now) | |
|
US10689346 (Pediatric) | BIOCRYST | NA |
Sep, 2035
(9 years from now) | |
|
US10662160 (Pediatric) | BIOCRYST | NA |
May, 2040
(14 years from now) | |
|
US10329260 (Pediatric) | BIOCRYST | NA |
Sep, 2035
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 03, 2025 |
| Orphan Drug Exclusivity(ODE-333) | Dec 03, 2027 |
| Pediatric Exclusivity(PED) | Jun 03, 2028 |
Drugs and Companies using BEROTRALSTAT HYDROCHLORIDE ingredient
NCE-1 date: 04 June, 2027
Market Authorisation Date: 03 December, 2020
Dosage: CAPSULE
More Information on Dosage
ORLADEYO family patents